Incyte Corporation News Releases https://investor.incyte.com/ Incyte Corporation News Releases en Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-results-phase-2-study-ruxolitinib 24-week results demonstrate significant improvement in repigmentation of facial vitiligo lesions after treatment with ruxolitinib cream Data presented at the World Congress of Dermatology support the planned initiation of a pivotal Phase 3 program, for which preparations are currently underway Sat, 15 Jun 2019 03:25:00 -0400 Incyte Corporation News Releases 20381 Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma https://investor.incyte.com/news-releases/news-release-details/incyte-announces-first-patient-treated-phase-3-clinical-trial-2 WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 4, 2019-- Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine Tue, 04 Jun 2019 07:30:00 -0400 Incyte Corporation News Releases 20346 New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib https://investor.incyte.com/news-releases/news-release-details/new-data-geometry-mono-1-study-show-clinically-meaningful Primary efficacy analysis demonstrated promising efficacy for capmatinib irrespective of the prior line of therapy in 97 patients: overall response rate was 68 percent and 41 percent and median duration of response was 11.14 months and 9.72 months, respectively, across treatment-naive and Mon, 03 Jun 2019 01:45:00 -0400 Incyte Corporation News Releases 20336 FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease https://investor.incyte.com/news-releases/news-release-details/fda-approves-jakafir-ruxolitinib-treatment-patients-acute-graft Jakafi is the first and only FDA -approved treatment for patients with steroid-refractory acute graft-versus-host disease (GVHD) WILMINGTON, Del. --(BUSINESS WIRE)--May 24, 2019-- Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Jakafi Fri, 24 May 2019 13:43:00 -0400 Incyte Corporation News Releases 20331 Incyte to Present at Upcoming Investor Conference https://investor.incyte.com/news-releases/news-release-details/incyte-present-upcoming-investor-conference-10 WILMINGTON, Del. --(BUSINESS WIRE)--May 23, 2019-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 40 th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho Palos Verdes. Thu, 23 May 2019 08:00:00 -0400 Incyte Corporation News Releases 20321 Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology https://investor.incyte.com/news-releases/news-release-details/data-incytes-inflammation-and-autoimmunity-portfolio-be-featured Investor conference call and webcast scheduled for Monday, June 17 at 8 a.m. EDT WILMINGTON, Del. --(BUSINESS WIRE)--May 20, 2019-- Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24 th World Congress Mon, 20 May 2019 07:30:00 -0400 Incyte Corporation News Releases 20311 Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA https://investor.incyte.com/news-releases/news-release-details/incyte-announces-abstracts-accepted-presentation-2019-asco WILMINGTON, Del. --(BUSINESS WIRE)--May 16, 2019-- Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting, to be held from May 31-June 4, Thu, 16 May 2019 12:00:00 -0400 Incyte Corporation News Releases 20306 Incyte to Present at Upcoming Investor Conferences https://investor.incyte.com/news-releases/news-release-details/incyte-present-upcoming-investor-conferences-37 WILMINGTON, Del. --(BUSINESS WIRE)--May 2, 2019-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at 8:40 am (PDT) in Las Vegas ; UBS Thu, 02 May 2019 08:00:00 -0400 Incyte Corporation News Releases 20281 Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2019-first-quarter-financial-results-and-provides Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019 Jakafi ® (ruxolitinib) revenues of $376 million in Q1   2019 (+20% vs Q1 2018), reaffirming full year 2019 revenue guidance range of $1.58-1.65 Tue, 30 Apr 2019 07:00:00 -0400 Incyte Corporation News Releases 20236 Incyte to Report First Quarter Financial Results https://investor.incyte.com/news-releases/news-release-details/incyte-report-first-quarter-financial-results-3 WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 11, 2019-- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its first quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2019 . The schedule for the press release and conference Thu, 11 Apr 2019 08:00:00 -0400 Incyte Corporation News Releases 20176